Specialty Pharmacy

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses how data connectivity is crucial for the specialty pharmacy industry.

Lack of federal oversight for cannabidiol products sold online could lead to adverse events among patients who take the products for conditions such as cancer.

Specialty pharmacists play a critical role in patient care.

Top news of the day from across the healthcare landscape.

Top news of the week from Specialty Pharmacy Times.

Study finds association between warfarin use and cancer incidence to determine whether warfarin has anticancer potential.

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Brentuximab vedotin (Adcetris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Ribociclib (Kisqali) combination therapy may improve survival among premenopausal breast cancer patients.

Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.

A comprehensive knowledge of the risk of breast cancer can lead to better screening.

Top news of the day from across the healthcare landscape.

MRI brain scans on children at high risk of multiple sclerosis may indicate earlier diagnoses and treatments.

Joel Wright, chief executive officer, Alliance Rx Walgreens Prime speaks to how medication synchronization programs can improve adherence.

Adalimumab-adbm (Cyltezo) showed equivalent safety and immunogenicity to adalimumab (Humira).

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus.

It will likely take decades to determine the long-term effects of cannabis, according to a session presented at the American College of Rheumatology Annual Meeting.

Top news of the day from across the healthcare landscape.

Nucala is an interleukin-5 antagonist under consideration as an add-on maintenance therapy for certain patients with chronic obstructive pulmonary disease.

Biosimilars have yet to make a significant impact on the prescription drug market.

FDA officials discuss safety data and drug approvals at the American College of Rheumatology Annual Meeting.

A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.

With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.

Mortality related to liver cirrhosis outpaces the rate for lung, colorectal, stomach, liver, and breast cancers.

Patients with osteoarthritis may be able to receive targeted therapy based on phenotypes.

Top news of the day from across the healthcare landscape.

Major adverse cardiovascular event rates for baricitinib stabilize over time.